Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.
复制标题
DOI：
10.1039/d1nr03831a
复制
发表时间：
2022-01-27
期刊：
影响因子：
6.7
通讯作者：
Li F
中科院分区：
文献类型：
--
作者：
Du L;Yang Y;Zhang X;Li F
COVID-19已造成全球大流行，数百万人死亡。当务之急是制定有效的对策，对病原体，SARS-CoV-2和它的许多变种。疫苗和治疗性抗体分别是预防和治疗COVID-19的最有效方法。SARS-CoV-2通过病毒表面S蛋白的活性进入宿主细胞。因此，S蛋白是疫苗和治疗性抗体的主要靶标。纳米技术处理纳米尺度的颗粒，已成为快速设计和开发安全，有效和急需的疫苗和治疗方法以控制COVID-19大流行病的关键工具。例如，纳米技术是快速批准两种mRNA疫苗在人群中广泛使用的关键。在这篇综述文章中，我们首先探讨了纳米技术在对抗COVID-19中的作用，包括蛋白质纳米颗粒（用于蛋白质疫苗的呈现），脂质纳米颗粒（用于与mRNA一起配制）和纳米抗体（作为独特的治疗性抗体）。然后，我们总结了目前可用的基于纳米技术的COVID-19疫苗和治疗方法。
COVID-19 has caused a global pandemic and millions of deaths. It is imperative to develop effective countermeasures against the causative viral agent, SARS-CoV-2 and its many variants. Vaccines and therapeutic antibodies are the most effective approaches for preventing and treating COVID-19, respectively. SARS-CoV-2 enters host cells through the activities of the virus-surface spike (S) protein. Accordingly, the S protein is a prime target for vaccines and therapeutic antibodies. Dealing with particles with dimensions on the scale of nanometers, nanotechnology has emerged as a critical tool for rapidly designing and developing safe, effective, and urgently needed vaccines and therapeutics to control the COVID-19 pandemic. For example, nanotechnology was key to the fast-track approval of two mRNA vaccines for their wide use in human populations. In this review article, we first explore the roles of nanotechnology in battling COVID-19, including protein nanoparticles (for presentation of protein vaccines), lipid nanoparticles (for formulation with mRNAs), and nanobodies (as unique therapeutic antibodies). We then summarize the currently available COVID-19 vaccines and therapeutics based on nanotechnology.
登录
查看更多内容
DOI：
10.1056/nejmoa2029849
发表时间：
2021-01-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
DOI：
10.1016/j.lanepe.2021.100252
发表时间：
2022-01
期刊：
The Lancet regional health. Europe
影响因子：
--
作者：
Allen H;Vusirikala A;Flannagan J;Twohig KA;Zaidi A;Chudasama D;Lamagni T;Groves N;Turner C;Rawlinson C;Lopez-Bernal J;Harris R;Charlett A;Dabrera G;Kall M;COVID-19 Genomics UK (COG-UK Consortium)
通讯作者：
COVID-19 Genomics UK (COG-UK Consortium)
影响因子：
4.8
作者：
Borggren, Marie;Nielsen, Jens;Fomsgaard, Anders
通讯作者：
Fomsgaard, Anders
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
4
作者：
Esquivel-Valerio JA;Skinner-Taylor CM;Moreno-Arquieta IA;Cardenas-de la Garza JA;Garcia-Arellano G;Gonzalez-Garcia PL;Almaraz-Juarez FDR;Galarza-Delgado DA
通讯作者：
Galarza-Delgado DA